These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35098846)

  • 21. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.
    Rizzo A; Federico AD; Ricci AD; Frega G; Palloni A; Pagani R; Tavolari S; Marco MD; Brandi G
    Cancer Control; 2020; 27(1):1073274820983013. PubMed ID: 33356500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted therapies in advanced biliary malignancies: a clinical review.
    Grewal US; Gaddam SJ; Beg MS; Brown TJ
    Expert Rev Anticancer Ther; 2024 Sep; 24(9):869-880. PubMed ID: 39083012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atezolizumab: an investigational agent for the treatment of biliary tract cancer.
    Hack SP; Zhu AX
    Expert Opin Investig Drugs; 2021 Oct; 30(10):1007-1015. PubMed ID: 34459336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.
    Schweitzer N; Vogel A
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):345-53. PubMed ID: 25966433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ivosidenib: an investigational drug for the treatment of biliary tract cancers.
    Angelakas A; Lamarca A; Hubner RA; McNamara MG; Valle JW
    Expert Opin Investig Drugs; 2021 Apr; 30(4):301-307. PubMed ID: 33683991
    [No Abstract]   [Full Text] [Related]  

  • 26. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
    Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current and novel therapeutic opportunities for systemic therapy in biliary cancer.
    Marin JJG; Prete MG; Lamarca A; Tavolari S; Landa-Magdalena A; Brandi G; Segatto O; Vogel A; Macias RIR; Rodrigues PM; Casta A; Mertens J; Rodrigues CMP; Fernandez-Barrena MG; Da Silva Ruivo A; Marzioni M; Mentrasti G; Acedo P; Munoz-Garrido P; Cardinale V; Banales JM; Valle JW; Bridgewater J; Braconi C;
    Br J Cancer; 2020 Sep; 123(7):1047-1059. PubMed ID: 32694694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular genetics and targeted therapeutics in biliary tract carcinoma.
    Marks EI; Yee NS
    World J Gastroenterol; 2016 Jan; 22(4):1335-47. PubMed ID: 26819503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biliary Tract Cancer: Molecular Biology of Precursor Lesions.
    Manzano-Núñez F; Prates Tiago Aguilar L; Sempoux C; Lemaigre FP
    Semin Liver Dis; 2023 Nov; 43(4):472-484. PubMed ID: 37944999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Not Available].
    Valéry M; Cervantes B; Smolenschi C; Boige V; Ducreux M; Cohen R; Hollebecque A
    Bull Cancer; 2022 Nov; 109(11S):11S21-11S27. PubMed ID: 36535759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The present roles and future perspectives of Interleukin-6 in biliary tract cancer.
    Zhou M; Na R; Lai S; Guo Y; Shi J; Nie J; Zhang S; Wang Y; Zheng T
    Cytokine; 2023 Sep; 169():156271. PubMed ID: 37331095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Familial Risk of Biliary Tract Cancers: A Population-Based Study in Utah.
    Samadder NJ; Smith KR; Wong J; Hanson H; Boucher K; Burt RW; Charlton M; Byrne KR; Gallegos-Orozco JF; Koptiuch C; Curtin K
    Dig Dis Sci; 2016 Dec; 61(12):3627-3632. PubMed ID: 27655103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
    Woo SM; Lee WJ; Han SS; Park SJ; Kim TH; Koh YH; Kim HB; Hong EK; Park JW; Kim CM
    Chemotherapy; 2012; 58(3):225-32. PubMed ID: 22831988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis.
    Dodoo GN; De B; Lee SS; Abi Jaoude J; Vauthey JN; Tzeng CD; Tran Cao HS; Katlowitz KA; Mandel JJ; Beckham TH; Minsky BD; Smith GL; Holliday EB; Koong AC; Das P; Taniguchi CM; Javle M; Koay EJ; Ludmir EB
    Oncologist; 2023 Apr; 28(4):327-332. PubMed ID: 36715178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Common DNA methylation changes in biliary tract cancers identify subtypes with different immune characteristics and clinical outcomes.
    Qiu Z; Ji J; Xu Y; Zhu Y; Gao C; Wang G; Li C; Zhang Y; Zhao J; Wang C; Wen X; Zhang Z; Li B; Zhang Z; Cai S; Li B; Jiang X
    BMC Med; 2022 Feb; 20(1):64. PubMed ID: 35130881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival outcome of patient with pT1N0 biliary tract cancer treated with surgery alone.
    Kagoura M; Kobayashi S; Kojima M; Kudo M; Sugimoto M; Konishi M; Gotohda N
    Eur J Surg Oncol; 2024 Mar; 50(3):107980. PubMed ID: 38281442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel insights into molecular and immune subtypes of biliary tract cancers.
    Bramel ER; Sia D
    Adv Cancer Res; 2022; 156():167-199. PubMed ID: 35961699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich.
    Zhang D; Dorman K; Heinrich K; Weiss L; Boukovala M; Haas M; Greif PA; Ziemann F; Beyer G; Roessler D; Goni E; Renz B; D'Haese JG; Kunz WG; Seidensticker M; Corradini S; Niyazi M; Ormanns S; Kumbrink J; Jung A; Mock A; Rudelius M; Klauschen F; Werner J; Mayerle J; von Bergwelt-Baildon M; Boeck S; Heinemann V; Westphalen CB
    Target Oncol; 2023 Sep; 18(5):767-776. PubMed ID: 37594677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives.
    Toledo B; Deiana C; Scianò F; Brandi G; Marchal JA; Perán M; Giovannetti E
    Expert Rev Clin Pharmacol; 2024 Apr; 17(4):323-347. PubMed ID: 38413373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy in Biliary Tract Cancers: Where Are We?
    Kalyan A; Khosla H; Kim RD
    Curr Oncol Rep; 2022 Dec; 24(12):1821-1828. PubMed ID: 36192517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.